文献速递治疗药物监测与药物基因组学特殊人群用药

城市内城区人群药物基因组学检测采纳的促进与阻碍因素

Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.
PubMed 文献 · Pharmacotherapy · 2018-01-21

该横断面调查于2014年3-4月从抗栓门诊招募120例患者,通过19题问卷评估城市内城区人群对药物基因组学检测的知识、态度与兴趣。研究发现促进因素包括提供检测信息、说明预测疗效的获益、信任医生决策及保险覆盖与可负担性;阻碍因素包括担忧结果负面后果、检测流程负担、隐私及保险覆盖问题。女性对检测感兴趣的调整比值比为4.2。

要点

  • 提供检测信息与说明预测疗效的获益是促进药物基因组学检测采纳的关键因素。
  • 担忧结果负面后果、检测流程负担及隐私与保险覆盖问题是主要阻碍因素。
  • 女性对药物基因组学检测感兴趣的调整比值比为4.2。

核心结论

  • 提供额外药物基因组学检测信息等促进因素与结果负面影响的感知及检测效用等阻碍因素,是 engaging 城市 largely minority 人群时需解决的问题。
  • 女性性别是药物基因组学检测兴趣的预测因素。

研究设计与样本

  • 横断面19题问卷调查,2014年3月至4月从抗栓门诊招募患者,面对面施测。
  • 共120例患者完成调查,平均年龄55.0±14.0岁,男性39.2%,非洲裔美国人69.2%。

主要发现

  • 促进因素包括提供进一步检测信息、说明检测预测治疗疗效的获益、患者信任医生做出正确基因型指导处方决策、保险覆盖与检测可负担性。
  • 阻碍因素包括担忧检测结果相关的负面后果、检测流程负担、老年及药物有效者感知缺乏效用、隐私问题、保险覆盖与检测可负担性担忧。
  • 女性对药物基因组学检测感兴趣的调整比值比为4.2。
  • 高兴趣患者中44.4%愿意支付20美元或更多,低兴趣患者中76.2%希望免费检测。

临床怎么用

  • 在向城市内城区人群推广药物基因组学检测时,应主动提供检测信息并说明其预测疗效的获益。
  • 需关注并回应患者对检测结果负面后果、流程负担、隐私及保险覆盖的担忧。

局限性

  • 单中心抗栓门诊招募,样本量120例,结果外推需谨慎。
  • 横断面设计无法确定因果关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine the knowledge, attitudes, and interest of an inner-city population toward pharmacogenetic testing, with the primary objective of identifying facilitators and barriers toward pharmacogenetic testing; and secondary objectives of determining predictors of patient interest in pharmacogenetic testing and how much patients would pay for the test. METHODS: Patients were recruited from an Antithrombosis Clinic from March to April 2014. A cross-sectional 19-question survey was administered in person to determine patients' knowledge and awareness of pharmacogenetic testing and collect demographic information. After explaining pharmacogenetics, patients ranked their interest toward the test and answered open-ended questions that elicited facilitators and barriers toward pharmacogenetic testing and elucidated how much patients would pay for testing. RESULTS: A total of 120 patients (mean age 55.0 ± 14.0 years, 39.2% male, 69.2% African American) were surveyed. Facilitators included providing further information about pharmacogenetic testing; elaborating on benefits of testing to predict treatment efficacy; patients' trust in their providers to make correct genotype-guided prescribing decisions; and insurance coverage and test affordability. Barriers to testing included concerns about the negative consequences associated with test results; burden of the testing process; perceived lack of utility among elderly and those whose medications were working; privacy issues; and concerns regarding insurance coverage and test affordability. Women had 4.2 times higher adjusted odds of being interested in pharmacogenetic testing. Almost half (44.4%) of the patients with high interest in the test were willing to pay $20 or more, whereas 76.2% of patients with low interest wanted testing at no cost. CONCLUSION: This study identified facilitators, such as providing additional pharmacogenetic test information, and barriers, such as perceived negative impact of the results and test utility, as issues to address when engaging an urban, largely minority population in pharmacogenetic testing. Female sex was a predictor of interest toward pharmacogenetic testing. These facilitators and barriers should be taken into consideration as pharmacogenetic testing gains widespread utility among inner-city populations.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Lee YM, Manzoor BS, Cavallari LH, et al. Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population. Pharmacotherapy. 2018. PMID: 29286540. doi:10.1002/phar.2077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。